Avis Budget Group, Inc. (CAR)
Can Higher Fleet Utilization Boost Avis Budget's Profitability?
CAR's stronger utilization and lower fleet costs lift second-quarter profits despite fewer vehicles and softer rental volumes.
Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way?
Cema-cel produced MRD clearance in 58.3% of treated patients versus 16.7% under observation. The 97.7% median ctDNA reduction by day 45 shows substantial early biological activity. FDA RMAT and Fast Track designations support the development strategy but do not prove durable efficacy.
Why Is Avis Budget (CAR) Down 7% Since Last Earnings Report?
Avis Budget (CAR) reported earnings 30 days ago. What's next for the stock?
Here's Why Investors Should Hold Avis Budget in Their Portfolios Now
CAR shares have jumped 57.8% in six months as rental demand, tech partnerships and buybacks support growth despite liquidity risks.
Adicet Bio: A Cheap Gamma Delta T-Cell Play
Adicet Bio offers a differentiated allogeneic gamma delta CAR-T platform targeting autoimmune diseases, trading below cash value with a pivotal readout imminent. Early prula-cel data in lupus nephritis showed 50% complete renal response and clean safety, supporting the curative CAR-T thesis versus chronic biologics. The upcoming 3Q 2026 readout on 22 patients is a binary catalyst; durability and long-term remission are critical for upside realization.
CAR Q2 Earnings Miss Puts Fleet Discipline and 2026 Guidance in Focus
Avis Budget's Q2 earnings miss exposed soft rental demand, while fleet cuts, record utilization and reaffirmed 2026 EBITDA guidance supported margins.
Is CAR Stock Worth Buying Despite Weak Liquidity and High Valuation?
Avis Budget's efficiency gains are lifting profits, but weak liquidity, high leverage and a premium valuation argue for patience.
Avis Budget Stock Plunges 17% Since Reporting Q2 Earnings Miss
CAR shares sink 16.5% after a Q2 earnings and revenue miss, even as fleet cuts drive record utilization and higher adjusted EBITDA.
Avis Budget Group Q2 Earnings Call Highlights
Avis Budget Group NASDAQ: CAR said it adjusted its fleet strategy during the second quarter of 2026 as travel demand softened from earlier expectations, reducing vehicle supply and emphasizing utilization, transaction profitability and returns over rental-day growth.
Compared to Estimates, Avis Budget (CAR) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Avis Budget (CAR) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Avis Budget Group (CAR) Lags Q2 Earnings and Revenue Estimates
Avis Budget Group (CAR) came out with quarterly earnings of $0.98 per share, missing the Zacks Consensus Estimate of $2.16 per share. This compares to earnings of $0.1 per share a year ago.
Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS
Kyverna Therapeutics is positioned to pioneer the autoimmune CAR T space, leveraging miv-cel as a potential first-in-class therapy for severe B-cell-driven autoimmune diseases. Recent regulatory alignment enables a rolling BLA submission for SPS, with pivotal single-arm Phase 2 data showing strong efficacy and safety, targeting FDA approval by late 2026. KYTX maintains a cash runway through 2028, supported by $236M in cash and a $150M credit facility, enabling completion of key trials and commercial launch preparation.
